The treatment decreased MMP-2 and MMP-7 mRNA expression, reduced VEGF protein expression, and downregulated the ERK and PI3 K/Akt pathways in the tumor tissue, attenuating the metastatic ability of the cancer cells. The gene discussed is MMP2; the disease is neoplasm.